Listen

Press releases

Receive e-mail alerts

Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
March 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results
March 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
March 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Planned Changes to Board Composition
February 09, 2026 at 01:00 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
January 08, 2026 at 01:00 PM UTC
Internal link ProQR to Participate in 8th Annual Evercore Healthcare Conference
December 01, 2025 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2025 Operating and Financial Results
November 06, 2025 at 12:00 PM UTC
Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
October 20, 2025 at 12:00 PM UTC
Internal link ProQR to Participate in Upcoming Investor Conferences in October 2025
October 13, 2025 at 12:30 PM UTC
Internal link ProQR Announces Second Quarter 2025 Operating and Financial Results
August 07, 2025 at 11:00 AM UTC
Internal link ProQR Announces Upcoming Presentation at RNA Editing Summit
July 28, 2025 at 12:00 PM UTC
Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
June 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
May 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results
May 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
May 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
May 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
April 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results
March 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
December 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results
November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets
September 27, 2023 at 11:00 AM UTC

Press releases

Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

Internal link ProQR Announces Year End 2025 Operating and Financial Results

Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

Internal link ProQR Announces Planned Changes to Board Composition

Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

Internal link ProQR to Participate in 8th Annual Evercore Healthcare Conference

Internal link ProQR Announces Third Quarter 2025 Operating and Financial Results

Internal link ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

Internal link ProQR to Participate in Upcoming Investor Conferences in October 2025

Internal link ProQR Announces Second Quarter 2025 Operating and Financial Results

Internal link ProQR Announces Upcoming Presentation at RNA Editing Summit

Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences

Internal link ProQR Announces First Quarter 2025 Operating and Financial Results

Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference

Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025

Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

Internal link ProQR Announces Year End 2024 Operating and Financial Results

Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results

Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing

Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets